JZJinming Zhang

Jinming Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinming Zhang has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Chuwei Zheng

    Department of Gastroenterology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China

    6 shared publications
  • Muxin Yu

    Department of Clinical Medical Sciences, College of Medicine, Jiaxing University, Jiaxing, Zhejiang, China

    4 shared publications
  • Xia Ji

    Department of Gastroenterology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China

    4 shared publications
  • Xiaowen Li

    Department of Pathology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China

    4 shared publications
  • Muxin Yu

    Department of Medicine, Jiaxing University, Jiaxing, China

    2 shared publications
  • Xiaoguang Wang

    Department of Hepatic Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China

    2 shared publications

Latest Publications

  • Mitochondrial dysfunction in MASH: Focusing on chronic inflammation and intercellular communication

    by Wanyi Luo, Muxin Yu, Chuwei Zheng, Xiaowen Li, Xiaotian Ma, Guocheng Zeng, Jinming Zhang, Xia Ji, Liyan Sun


  • A rare case of urachal cyst in the ascending colon of an adult patient

    by Yangming Que, Chuwei Zheng, Jinming Zhang, Muxin Yu, Xiaowen Li

  • Open Access

    Phosphatidylserine induce thrombotic tendency and liver damage in obstructive jaundice

    by Muxin Yu, Chuwei Zheng, Xiaoguang Wang, Rong Peng, Guoming Lu, Jinming Zhang

    Hypercoagulability contributes to the majority of deaths and organ failure associated with obstructive jaundice (OJ). However, the exact mechanism of the coagulopathy in OJ remains elusive. Our objectives were to demonstrate whether phosphatidylserine (PS) exposure on blood cells (BCs), microparticles (MPs), and endothelial cells (ECs) can account for the hypercoagulability and liver damage in OJ patients. We evaluated OJ patients at two time point, which before (Day 0) and 7 days (Day 7) after the endoscopic retrograde cholangiopancreatography procedure (ERCP), and compared with healthy controls. Lactadherin was used to quantify PS exposure on BCs, MPs and ECs. Human umbilical vein endothelial cells (HUVECs) were incubated with serum of OJ patients and the expression of PS were evaluated. Meanwhile, healthy BCs and HUVECs were treated with 0, 25, 50 or 100µM unconjugated bilirubin (UCB) and PS exposure on cells were evaluated. Procoagulant activity was evaluated by purified coagulation complex assays, clotting time, and fibrin turbidity. In addition, we established a cholestatic mouse model by bile duct ligation to determine the potential role of PS in intrahepatic coagulation and liver damage. Using flow cytometry, we found that OJ patients exhibited elevated levels of PS + BCs and associated MPs compared to the controls. Furthermore, the number of PS + BCs and MPs in patients at Day 0 were significantly higher than in patients at Day 7. Similarly, we observed markedly elevated PS exposure on HUVECs cultured with serum from patients at Day 0 versus serum from patients at Day 7. In vitro assays, PS exposure on BCs and HUVECs progressively increased with the concentration of UCB. Moreover, PS + BCs and MPs contributed to greatly shortened coagulation time and markedly enhanced coagulation factor Xa, thrombin, and fibrin generation. This procoagulant activity could be blocked approximately 80%, by the addition of lactadherin. Moreover, cholestatic mice exhibited significantly increased levels of liver tissue necrosis, fibrin deposition, and thrombophilia compared to sham mice. The enhanced intrahepatic coagulation and liver injury could be reversed by inhibiting PS with lactadherin. These results highlight the pathogenic activity of PS + cells and MPs in promoting a prothrombotic environment and liver damage in OJ. As such, lactadherin, a PS blockade, may be a viable therapeutic strategy for treating such patients.


  • Open Access

    Correlation between PDGF-BB and M1-type macrophage in inflammatory bowel disease: a case-control study

    by Zhiyun Fang, Siwen Qu, Xia Ji, Chuwei Zheng, Juanfen Mo, Jianqiu Xu, Jinming Zhang, Haiyan Shen

    Inflammatory bowel disease (IBD) is a chronic disease in which macrophages play an important role in its pathogenesis. Platelet-derived growth factor-BB (PDGF-BB) secreted by macrophages is involved in the repair of vascular endothelial injury during inflammatory reactions. The expression levels of M1 macrophages and PDGF-BB in serum and colonic mucosa of 30 patients with Crohn’s disease (CD) and 30 patients with ulcerative colitis (UC) were measured using enzyme-linked immunosorbent assays and immunohistochemistry. Logistic regression was used for univariate and multivariate analyses, and receiver operating characteristic curves were used to evaluate diagnostic value. Associations were evaluated using Spearman correlation analysis. The expression of serum PDGF-BB and M1 macrophages with positive CXCL9 expression in patients with active-stage IBD [206.55(160.41,262.90)and 337.30(217.73,472.28) pg/ml] was higher than that in patients with remission stage [153.42(107.02,219.68)and 218.37(144.49,347.33)pg/ml] and controls [156.19(91.16,216.08)and 191.20(121.42,311.76)pg/ml](P < 0.05). The expression of PDGF-BB, CD86, and CXCL9 in the colon of patients with active-stage IBD [0.380(0.266,0.542) 0.663(0.480,0.591) and 0.564(0.378,0.765) /µm2] was higher than that in the remission stage [0.308(0.214,0.420), 0.376(0.206,0.591) and 0.413(0.275,0.570) /µm2] and controls [0.265(0.185,0.384), 0.416(0.269,0.534) and 0.497(0.415,0.642) /µm2] (P < 0.05). A positive correlation was observed between CD86 and PDGF-BB, and CXCL9 and PDGF-BB levels in patients with IBD (P < 0.05). CD86 and PDGF-BB in the colonic mucosa were independent risk factors for active IBD, and the area under the curve for their combined diagnosis was 0.754 (95%CI: 0.654–0.852, P < 0.05). PDGF-BB was associated with M1 macrophages and has a potential diagnostic value for active IBD. Not applicable. A potential correlation was observed between PDGF-BB and M1 macrophages. CD86 and PDGF-BB in colonic mucosa were independent risk factors for active IBD. PDGF-BB and M1 macrophages with positive CXCL9 expression were significantly increased during active IBD.


  • Open Access

    Neutrophil extracellular traps induce intrahepatic thrombotic tendency and liver damage in cholestatic liver disease

    by Muxin Yu, Xiaowen Li, Long Xu, Chuwei Zheng, Weiwei Pan, Hui Chen, Xiaoyu Liu, Xianshan Zhang, Jinming Zhang

    Background: Cholestatic liver diseases induce local and systemic hypercoagulation, with neutrophil extracellular traps (NETs) serving as major drivers. These NETs have been linked to decreased liver function in patients with obstructive jaundice. However, the impact of NETs on liver hypercoagulation in cholestatic liver disease remains unknown. Methods: We utilized bile duct ligation to create experimental mice and analyzed NETs formation in the liver. Fibrin deposition, tissue factor expression, and inflammation in the liver were visualized through western blot and immunohistochemical techniques. LSECs were incubated with isolated NETs, and we detected endothelial procoagulant activity using coagulation protein production assays and measuring endothelial permeability. In both in vivo and in vitro settings, DNase I was applied to clarify the effect of NETs on intrahepatic hypercoagulability, hepatotoxicity, LSEC, and macrophage activation or injury. Results: Bile duct ligation mice exhibited significantly increased levels of NETs in liver tissue, accompanied by neutrophil infiltration, tissue necrosis, fibrin deposition, and thrombophilia compared to sham mice. Notably, NETs resulted in phosphatidylserine and tissue factor exposure on LSEC, enhancing coagulation Factor Xa and thrombin production. The enhanced procoagulant activity could be reversed by degrading NETs with DNase I. Additionally, NETs-induced permeability changes in LSECs, characterized by increased VE-cadherin expression and F-actin retraction, which could be rescued by DNase I. Meanwhile, NET formation is associated with KC activation and the formation of inflammatory factors. Conclusions: NETs promote intrahepatic activation of coagulation and inflammation, leading to liver tissue injury. Strategies targeting NET formation may offer a potential therapeutic approach for treating cholestatic liver disease.